Louise Chen
Stock Analyst at Cantor Fitzgerald
(3.08)
# 1,339
Out of 4,761 analysts
283
Total ratings
41.91%
Success rate
1.46%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $0.83 | - | 5 | Nov 15, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $88.08 | +81.65% | 20 | Nov 6, 2024 | |
| PCVX Vaxcyte | Reiterates: Overweight | n/a | $79.74 | - | 6 | Nov 6, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $26.30 | +71.10% | 30 | Oct 25, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $33.78 | - | 7 | Oct 25, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $162.30 | +32.47% | 40 | Oct 16, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $7.68 | - | 5 | Oct 11, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $89.50 | +73.18% | 25 | Oct 3, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $10.68 | - | 9 | Sep 19, 2024 | |
| LLY Eli Lilly and Company | Reiterates: Overweight | $885 | $873.68 | +1.30% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.99 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.27 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.37 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.21 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.54 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $202.08 | -1.03% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.08 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.80 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.06 | - | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.23 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.59 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.34 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $700.33 | +32.08% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.07 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $10.47 | +520.82% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.24 | - | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.87 | +474.65% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.97 | +2,477.32% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.11 | +210.37% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.02 | +284.02% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.30 | +284.62% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $2.74 | +228.47% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $21 | $0.43 | +4,783.72% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67,500 | $0.86 | +7,884,492.92% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $461.78 | -44.13% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.74 | -10.39% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.73 | +2,790.17% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.68 | +1,090.48% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.19 | +767.05% | 1 | Jun 22, 2017 |
Spero Therapeutics
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.83
Upside: -
Novo Nordisk
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $88.08
Upside: +81.65%
Vaxcyte
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $79.74
Upside: -
Pfizer
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $26.30
Upside: +71.10%
Zai Lab
Oct 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.78
Upside: -
Johnson & Johnson
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $162.30
Upside: +32.47%
Zevra Therapeutics
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.68
Upside: -
Merck & Co.
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $89.50
Upside: +73.18%
Roivant Sciences
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.68
Upside: -
Eli Lilly and Company
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $873.68
Upside: +1.30%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.99
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.27
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.37
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.21
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.54
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $202.08
Upside: -1.03%
Aug 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.08
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.80
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.06
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.23
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.59
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.34
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $700.33
Upside: +32.08%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.07
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $10.47
Upside: +520.82%
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.24
Upside: -
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.87
Upside: +474.65%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.97
Upside: +2,477.32%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.11
Upside: +210.37%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.02
Upside: +284.02%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.30
Upside: +284.62%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.74
Upside: +228.47%
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $0.43
Upside: +4,783.72%
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $0.86
Upside: +7,884,492.92%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $461.78
Upside: -44.13%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.74
Upside: -10.39%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.73
Upside: +2,790.17%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.68
Upside: +1,090.48%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.19
Upside: +767.05%